88 completed, 20 active not recruiting, 19 recruiting, 16 terminated. 158 Phase 3, 21 Phase 2.
Follow Avastin: new trials by email Literature Review of Avastin trials Research Report on Avastin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Sacituzumab tirumotecan, Bevacizumab, Rescue Medications - Ovarian Neoplasms, Ovarian Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 900 | 2026-02-16 | 2026-10-13 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer PF-08634404, Bevacizumab, Chemotherapy - Intestinal Neoplasms, Gastrointestinal Neoplasms | Phase 3 | Recruiting | Pfizer | 800 | 2025-12-11 | 2026-10-08 |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 477 | 2025-07-16 | 2026-10-07 |
| Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases Bevacizumab, Dexamethasone - Radiation Necrosis, High Grade Glioma (III or IV) | Phase 3 | Recruiting | The Netherlands Cancer Institute | 408 | 2025-06-19 | 2026-07-13 |
| Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases Bevacizumab, Placebo, Prednisolone - Radionecrosis of Brain, Brain Metastases | Phase 3 | Recruiting | Institut Cancerologie de l'Ouest | 84 | 2025-04-29 | 2025-08-17 |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 770 | 2025-04-09 | 2026-10-13 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Amivantamab, Cetuximab, Bevacizumab - Colorectal Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 700 | 2024-12-12 | 2026-09-25 |
| A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Recruiting | NaviFUS Corporation | 32 | 2024-11-08 | 2026-04-09 |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 408 | 2024-04-10 | 2026-09-24 |
| Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients Oxaliplatin, Fluorouracil, Serplulimab - Colorectal Cancer, Liver Metastases | Phase 2 / Phase 3 | Recruiting | Sun Yat-sen University | 156 | 2024-02-01 | 2026-04-20 |
| A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) Atezolizumab, Bevacizumab, Tiragolumab - Hepatocellular Carcinoma | Phase 3 | Active not recruiting | Hoffmann-La Roche | 687 | 2023-09-14 | 2025-12-31 |
| Evaluating Novel Therapies in ctDNA Positive GI Cancers Atezolizumab, Bevacizumab - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | Active not recruiting | Georgetown University | 11 | 2023-03-29 | 2026-10-06 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) Bevacizumab, Ranibizumab Ophthalmic - Wet Age-related Macular Degeneration | Phase 3 | Recruiting | Parc de Salut Mar | 630 | 2022-11-18 | 2025-11-20 |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer tucatinib, trastuzumab, bevacizumab - Colorectal Neoplasms | Phase 3 | Recruiting | Seagen, a wholly owned subsidiary of Pfizer | 400 | 2022-10-24 | 2026-07-22 |
| A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP Bevacizumab, Laser - Retinopathy of Prematurity | Phase 3 | Terminated | Jaeb Center for Health Research | 16 | 2022-04-27 | 2026-09-14 |
Showing 20 of 158. Sign in to see all of them.
Colorectal Neoplasms (31) · Ovarian Neoplasms (14) · Breast Neoplasms (12) · Carcinoma, Hepatocellular (10) · Carcinoma, Non-Small-Cell Lung (10) · Colonic Neoplasms (9) · Neoplasms (9) · Fallopian Tube Neoplasms (8) · Glioblastoma (7) · Rectal Neoplasms (7) · Macular Degeneration (6) · Macular Edema (6) · Neoplasm Metastasis (5) · Brain Neoplasms (4) · Brenner Tumor (4)
National Cancer Institute (NCI) (32) · Hoffmann-La Roche (27) · Merck Sharp & Dohme LLC (4) · Genentech, Inc. (3) · Pfizer (3) · Amgen (2) · AstraZeneca (2) · Boehringer Ingelheim (2) · Bristol-Myers Squibb (2) · ECOG-ACRIN Cancer Research Group (2) · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA (2) · Jaeb Center for Health Research (2) · NRG Oncology (2) · National Cancer Institute, Naples (2) · Sumitomo Pharma America, Inc. (2)
United States (83) · Spain (44) · Italy (38) · Canada (37) · France (37) · Germany (32) · Japan (31) · China (30) · South Korea (29) · Brazil (26) · Australia (23) · Poland (23) · Belgium (22) · Taiwan (22) · Netherlands (21)
Charles Blanke (2) · Hope S Rugo (2) · Reinier O Schlingemann, MD, PhD (2) · Aarti Bhatia (1) · Aidong Qu, Master (1) · Al B Benson (1) · Al Benson (1) · Alan Sandler (1) · Alicia Pareja, MD (1)
PMID 37185961, PMID 34616010, PMID 21941283, PMID 29522361, PMID 31276981, PMID 34028627, PMID 12636887, PMID 17167137, PMID 18160686, PMID 18824714, PMID 20573926, PMID 21526923, PMID 21705281, PMID 21874312, PMID 21997132, PMID 22150050, PMID 22204724, PMID 22240792, PMID 22452699, PMID 22512984, PMID 22555112, PMID 22776937, PMID 22939114, PMID 23047002, PMID 23168366, PMID 23219660, PMID 23233715, PMID 23292928, PMID 23337555, PMID 23529375, PMID 23642377, PMID 23706946, PMID 23816960, PMID 23852309, PMID 23916488, PMID 23932548, PMID 24028813, PMID 24084496, PMID 24314839, PMID 24552317, PMID 24552318, PMID 24552320, PMID 24637997, PMID 24652518, PMID 24687829, PMID 24727261, PMID 24794243, PMID 24835760, PMID 24875610, PMID 24895339
U10CA180868 (12), 2023 (7), U10CA021115 (7), U10CA027469 (7), U10CA180820 (7), U10CA031946 (6), U10CA032102 (5), 2014 (4), 2018 (4), U10CA180821 (4), 2019 (3), U10CA180888 (3), 2016 (2), 2005 (1), 2008 (1)